Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

BACKGROUND: Ofatumumab (Arzerra(®), Novartis) is a treatment for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [double refractory (DR-CLL)]. Ofatumumab was licensed on the basis of an uncontrolled Phase II study, Hx-CD20-406, in which patients receiving ofatumumab survived f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatswell, Anthony J., Thompson, Gwilym J., Maroudas, Penny A., Sofrygin, Oleg, Delea, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446681/
https://www.ncbi.nlm.nih.gov/pubmed/28559746
http://dx.doi.org/10.1186/s12962-017-0071-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446681/
https://www.ncbi.nlm.nih.gov/pubmed/28559746
http://dx.doi.org/10.1186/s12962-017-0071-x

Ejemplares similares